Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10609/93055
Título : | Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? |
Autoría: | Catalán Alonso, Maria José Antonini, Angelo Calopa Garriga, Matilde Bajenaru, Ovidiu Fàbregues, Oriol de Mínguez Castellanos, Adolfo Odin, Per García Moreno, José Manuel Pedersen, Stephen W. Pirtosek, Zvezdan Kulisevsky, Jaime |
Otros: | Hospital Clínico San Carlos IRCCS Ospedale San Camillo Hospital Universitari de Bellvitge Carol Davila University of Medicine and Pharmacy Vall d'Hebron Barcelona Hospital Campus Complejo Hospitalario Universitario de Granada Lund University Hospital Universitario Virgen Macarena University of Copenhagen University Medical Centre Ljubljana Universitat Oberta de Catalunya |
Citación : | Catalán, M.J., Antonini, A., Calopa, M., Bajenaru, O., Fàbregues, O. de, Mínguez-Castellanos, A., Odin, P., García-Moreno, J.M., Pedersen, S., Pirtosek, Z. & Kulisevsky, J. (2017). Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. eNeurologicalSci, 8(), 44-53. doi: 10.1016/j.ensci.2017.06.004 |
Resumen : | Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by motor complications, the presence of axial symptoms, and emergent disease- and drug-related non-motor symptoms. One of the advanced therapies available is intrajejunal infusion of levodopa/carbidopa intestinal gel (LCIG); however, patient selection for this treatment is sometimes difficult, particularly because of overlapping indications with other alternatives. In recent years, strong evidence has supported the use of LCIG in treating motor fluctuations associated with APD, and several clinical studies provide emerging evidence for additional benefits of LCIG treatment in certain patients. This article provides an overview of the published literature on the benefits, limitations, and drawbacks of LCIG in relation to PD symptoms, the psychosocial impact of the disease, and the quality of life of patients, with the aim of determining candidates for whom treatment with LCIG would be beneficial. According to current evidence, patients with APD (defined as inability to achieve optimal control of the disease with conventional oral treatment), a relatively well-preserved cognitive-behavioral status, and good family/caregiver would count as suitable candidates for LCIG treatment. Contraindications in the opinion of the authors are severe dementia and active psychosis. |
Palabras clave : | enfermedad de Parkinson infusión intrayeyunal de levodopa/carbidopa gel intestinal duodopa síntomas motores calidad de vida síntomas no motores |
DOI: | 10.1016/j.ensci.2017.06.004 |
Tipo de documento: | info:eu-repo/semantics/review |
Versión del documento: | info:eu-repo/semantics/publishedVersion |
Fecha de publicación : | 2-jul-2017 |
Licencia de publicación: | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ |
Aparece en las colecciones: | Articles Articles cientÍfics |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
levodopa.pdf | 299,03 kB | Adobe PDF | Visualizar/Abrir |
Comparte:
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons